Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

Zukin1, Mauro; Gondim2, Victor; Shimada3, Andrea Kazumi; Lima4, Ellias Magalhães e Abreu; Mathias5,6, Clarissa; Barra7, Williams Fernandes; Junior8,9, William Nassib William; Padoan2, Mônica; Bittencourt3a, Yuri; Yamamura8, Rosely; Silva10, Carlos Eduardo Baston; Rossato11, Letícia de Jesus; Monteiro1, Caio de Almeida; Jesus12, Rafaela Gomes de; Gössling12, Gustavo; Gelatti13, Ana Caroline Zimmer

97
Views

Back to summary

Open Access

Peer-Reviewed
Artigo Original

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

Mauro Zukin1, Victor Gondim2, Andrea Kazumi Shimada3, Ellias Magalhães e Abreu Lima4, Clarissa Mathias5,6, Williams Fernandes Barra7, William Nassib William Junior8,9, Mônica Padoan2, Yuri Bittencourt3a, Rosely Yamamura8, Carlos Eduardo Baston Silva10, Letícia de Jesus Rossato11, Caio de Almeida Monteiro1, Rafaela Gomes de Jesus12, Gustavo Gössling12, Ana Caroline Zimmer Gelatti13

How to cite this article

Zukin1 M, Gondim2 V, Shimada3 AK, Lima4 EMeA, Mathias5 C, 6 , et al. Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120). J Bras Pneumol. 2024;50(6):e20240228